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Six distinct peroxiredoxin (Prx) proteins (Prx I-VI)
from distinct genes have been identified in mammalian
tissues. Prxs are members of a group of peroxidases that
have conserved reactive cysteine residue(s) in the active
site(s). An immediate physiological electron donor for
the peroxidase catalysis for five Prx proteins (Prx I-V)
has been identified as thioredoxin (Trx), but that for Prx
VI (1-Cys Prx) is still unclear. To identify an immediate
electron donor and a binding protein for Prx VI, we
performed a Prx VI protein overlay assay. A 20-kDa
binding protein was identified by the Prx VI protein
overlay assay with flow-through fractions from a High-Q
column with rat lung crude extracts. Using matrix-
assisted laser desorption/ionization time-of-flight mass
spectrometry (MALDI-TOF) and MS-Fit, we identified the
20-kDa Prx VI-binding protein as a cyclophilin A (CyP-A).
The binding of recombinant human CyP-A (hCyP-A) to
Prx VI was confirmed by using the hCyP-A protein over-
lay assay and Western immunoblot analysis with hCyP-A-
specific antibodies. hCyP-A enhanced the antioxidant ac-
tivity of Prx VI, as well as the other known mammalian
Prx isotypes. hCyP-A supported antioxidant activity of
Prx II and Prx VI both against thiol (dithiothreitol)-con-
taining metal-catalyzed oxidation (MCO) systems and
ascorbate-containing MCO systems. Prx II was reduced
by hCyP-A without help from any other reductant, and
the reduction was cyclosporin A-independent. These re-
sults strongly suggest that CyP-A not only binds to Prx
proteins but also supports its peroxidase activity as an
immediate electron donor. In addition, Cys115 and Cys161
of hCyP-A were found to be involved in the activation and
the reduction of Prx.
Peroxiredoxin (Prx)1 is a member of a growing family of thiol
peroxidases that reduce peroxides to corresponding alcohols
using reactive cysteine residue(s) in its active center (1). Recent
searches of the public data bases show more than 100 members
of the Prx family from archaebacteria to human. All of the Prx
family members that have been examined for their antioxidant
capacity show a measurable protection of glutamine synthetase
(GS) inactivation against oxidative insults (1–9). Their GS pro-
tection capability is caused by peroxide reducing activity in the
presence of an appropriate electron donor such as thioredoxin
(Trx). All Prx family members that contain two conserved cys-
teine residues (Prx I-IV) and one member containing one con-
served cysteine residue (Prx V) have an H2O2 reducing activity
that uses thioredoxin as an immediate electron donor and is
thus named thioredoxin peroxidase (TPx) (9–12).
Recently, another member of the Prx family containing only
one conserved cysteine residue (1- Cys Prx, later classified as a
Prx VI) has been identified in several organisms (5, 13–18). In
barley seeds, a functional relationship of this protein to dor-
mancy has been reported (13); however, transgenic tobacco that
overexpress 1-Cys Prx (Prx VI) of rice do not exhibit this cor-
relation (14).
Glutathione peroxidase (GPx) and phospholipase A2 bifunc-
tional enzymatic activities in recombinant human Prx VI have
recently been confirmed (15–16). Recombinant Prx VI protein
reduced hydrogen peroxide, as well as phospholipid hydroper-
oxides, in the presence of GSH (17). Bovine and mouse coun-
terparts were reported to have a novel GPx activity that does
not contain selenium at its active site (18–19). Although the
GPx activity of Prx VI has been confirmed, peroxidase activity
of Prx VI in the presence of GSH was generally much lower
than that with dithiothreitol (DTT), while the GS protection
activity of Prx VI in the presence of DTT was comparable with
selenium-GPx as well as other Prx members (5). Thus, the
presence of other physiological electron donors was suggested.
To identify the possible electron donor or the protein functionally
linked to Prx VI, we performed a Prx VI protein overlay assay with
fractionated rat lung crude extracts. We have now shown that
cyclophilin A (CyP-A) binds to Prx VI and enhances its antioxidant
activity. We also provide evidence that CyP-A can be a general
electron donor for all known mammalian Prx isotypes.
EXPERIMENTAL PROCEDURES
Materials—GS was purified from Escherichia coli K12 as described
previously (20). Recombinant human Prx proteins were purified from
the E. coli overexpression system as previously described (4–5, 10).
Polyclonal antiserum to Prx VI and human CyP-A (hCyP-A) were pre-
pared from rabbits by injecting purified recombinant Prx VI and
hCyP-A, respectively.
Nitrocellulose membrane (BA-85) was obtained from Schleicher and
Schuell, and the alkaline phosphatase-labeled anti-rabbit IgG produced
in goat was purchased from KPL Laboratories.
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Fractionation of Rat Lung Crude Extract with High-Q Anion-Ex-
change Column Chromatography—Rat lungs (10 g) were homogenized
with 20 ml of 20 mM Tris-HCl buffer (pH 7.6) containing 100 g/ml of
phenylmethylsulfonyl fluoride, and the homogenate was centrifuged for
30 min at 20,000  g. The clear supernatant was applied to a High-Q
strong anion-exchange column (Econo-pac, 5 ml, Bio-Rad) that had been
equilibrated with 25 mM Tris-HCl (pH 7.6). After washing for 10 min
with equilibration buffer, proteins were eluted with a linear NaCl
gradient from 0 to 1 M for 200 min. The flow rate was 0.5 ml/min and
5-ml fractions were collected.
Overlay Assay—Proteins in the fractions eluted from the High-Q
column were separated by SDS-PAGE (13.5%), and the separated pro-
teins were electroblotted to a nitrocellulose membrane. After blocking
with 3% bovine serum albumin and washing with TBST (20 mM Tris-Cl,
pH 8.0, 150 mM NaCl, 0.05% Tween 20), the membrane (in TBST) was
incubated overnight with 5 g/ml of purified recombinant Prx VI at
4 °C. After subsequent washing with TBST, the membrane was incu-
bated with Prx VI-specific antiserum for an additional 4 h at 4 °C.
Immune complexes of Prx VI were visualized with an alkaline phos-
phatase-conjugated secondary antibody by phosphatase reaction. Ex-
cept for incubation with Prx VI, the same procedures were applied to
the control membrane.
MALDI-TOF Analysis—Fractions eluted from the High-Q column
that contained putative Prx VI-binding proteins were separated on a
13.5% SDS-PAGE gel, and the proteins were visualized with Coomassie
Brilliant Blue R-250. The stained protein band that corresponds to the
position of the putative Prx VI-binding protein was excised and succes-
sively washed with 30% ethanol and 100% acetonitrile. After drying the
gel pieces in a SpeedVac (Savant) for 30 min, a rehydration and prote-
olysis was done by adding 12.5 g/ml of trypsin at 37 °C for 12 h in a 25
mM ammonium bicarbonate buffer (pH 8.0). Resulting trypsinized pep-
tides were analyzed using a MALDI-TOF mass spectrometer equipped
with delayed ion extraction (VOYAGER-DE STR, PE Biosystems).
Bacterial Expression and Purification of Recombinant WT and Mu-
tant CyP-A—cDNA encoding hCyP-A was amplified by polymerase
chain reaction (PCR) from a U-937 human histiocytic lymphoma cell
cDNA library. The primers for amplified hCyP-A were designed based
on the reported human T-cell cyclophilin cDNA sequence (21). Primers
for hCyP-A are as follows; 5-CyP (5-GCCCATATGGTCAACCCCAC-
CGTGTTC-3), which contains an initiation codon (italicized) and an
NdeI site (underlined), and 3-CyP (3-ACACCTGTTGAGCTTATTC-
CTAGG GTT-5), which contains a stop codon (italicized) and a BamHI
site (underlined). Four cysteine residues (Cys52, Cys62, Cys115, and
Cys161) of hCyP-A were individually mutated to serine by recombinant
PCR (C52S, C62S, and C115S) or a standard PCR-mediated amplifica-
tion with a mismatched 3-primer (C161S). The primers for cysteine to
serine mutants (C52S, C62S, C115S, and C161S) are as follows; 5-C-
52S (5-TATAAGGGTTCCTCCTTTCACAGA-3) and 3-C52S (3-ATA-
TTCCCAAGGAAAGTGTCT-5); 5-C62S (5-CCAGGGTTTATGTCTC-
AGGGTGGT-3) and 3-C62S (3-GGTCCCAAATACAGAGTCCCACC-
ACCA-5); 5-C115S (5-CAGTTTTTCATCTCCACTGCCAAG-3) and
3-C115S (3-GTCAAAAAGTAGAGGTCACGGTTC-5); 5-CyP (desc-
ribed above) and 3-C161S (3-TGGTAACGACTGAGACCTGTTCACC-
TTATTCCTAGGGTT-5); primers containing a mismatch is double
underlined, the stop codon is italicized and the BamHI site is un-
derlined. The PCR products (WT, C52S, C62S, C115S, and C161S) were
cloned into a pCR 2.1-TOPO vector (Invitrogen), and the sequence of
amplified WT and mutant hCyP-A cDNAs were confirmed with an
automated fluorescence dye DNA sequencer (ABI Prism 377, KBSI
Gwangju). The NdeI-BamHI fragment from pCR 2.1-TOPO containing
recombinant hCyP-A cDNAs were then transferred to a pET-17b (Nova-
gen) expression plasmid.
The E. coli BL21(DE3)pLysS was transformed with pET-17b-con-
taining recombinant hCyP-A cDNAs, and then the recombinant WT and
mutant hCyP-A proteins were induced using isopropyl-1-thio--D-galac-
topyranoside. Recombinant hCyP-A proteins were purified with the
combined methods of ammonium sulfate fractionation, DEAE-Sephacel
anion-exchange column chromatography, and HPLC TSK heparin
5-PW column chromatography (wild type) or Sephacryl S-100 gel filtra-
tion column chromatography (mutants). The molecular size and purify
of recombinant hCyP-A proteins were confirmed by 15% SDS-PAGE
analysis.
Antioxidant Activity Assay—GS was oxidatively inactivated either by
the thiol (DTT)- or ascorbate-containing metal-catalyzed oxidation
(MCO) system (2). The ability of Prx VI to protect GS from the oxidative
insult generated either by ascorbate or thiol (DTT) systems was meas-
ured in the presence or absence of recombinant hCyP-A. A reaction
mixture (25 l) containing 0.5 g of GS, 10 mM DTT, or ascorbate, 5 M
(with DTT) or 12.5 M (with ascorbate) FeCl3, 50 mM Hepes-NaOH (pH
7.0), and Prx VI and/or hCyP-A was incubated at 30 °C for 10 min to
inactivate GS. The remaining activity of GS was measured by adding a
-glutamyltransferase assay mixture at 30 °C for 5 min. Absorbance
resulting from the -glutamylhydroxamate-Fe3 complex was meas-
ured at 540 nm.
RESULTS
Fractionation of Rat Lung Crude Extract and Overlay of Prx
VI—To search for the putative Prx VI-binding protein, we first
tried the overlay assay on a protein blot prepared from rat lung
crude extract after separation on an SDS-PAGE gel. Various
protein bands representing potential Prx VI complexes were
visualized on the blotted membrane; however, because of low
resolution, it was not easy to identify the corresponding protein
band on the Coomassie Blue-stained SDS-PAGE gel (data not
shown). Sufficient resolution was acquired with a High-Q an-
ion-exchange column-fractionated rat lung crude extract.
Three tentative Prx VI-binding proteins (Fig. 1B, marked as
arrows) were successfully detected from the flow-through frac-
tions (Fig. 1A), whereas the non-overlaid control did not show
any noticeable positives when probed with Prx VI-specific an-
tibody (Fig. 1C). Several minor protein band complexes with
Prx VI were also visible at around 150 kDa or larger and less
than 10 kDa (Fig. 1B).
Identification of the Prx VI-binding Protein by MALDI-
FIG. 1. Prx VI overlay assay. A, rat lung crude extract was frac-
tionated on a High-Q anion-exchange column with a linear NaCl gra-
dient from 0 to 1 M for 200 min. The flow rate was 0.5 ml/min, and 5-ml
fractions were collected. Fractions of dotted protein peak were used for
Prx VI overlay assay. B, proteins in the fractions from High-Q column
chromatography (fraction 2–9) were separated on a 13.5% SDS-PAGE
gel and electroblotted to a nitrocellulose membrane. Prx VI was over-
laid on the nitrocellulose membrane and resulting Prx VI complexes
were visualized with Prx VI-specific antiserum as described under
“Experimental Procedures.” Lane S contains 100 ng of purified recom-
binant Prx VI. C, all the procedures were the same as those used for
panel B except for the Prx VI overlay. Lane S contains 300 ng of purified
recombinant Prx VI. D, electroblotted nitrocellulose membrane was
probed with hCyP-A specific antiserum. Lane S contains 200 ng of
purified recombinant hCyP-A.
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TOF—Among the three candidates (about 34, 27, and 20 kDa),
we focused our efforts on the characterization of the smallest
protein (20 kDa). After separation of the proteins in fraction
number 4 (Fig. 1A) on a 12.5% SDS-PAGE gel, the protein band
at around 20 kDa that corresponded to the position of a positive
signal on the overlay assay was excised after Coomassie Blue
staining. Proteins in the excised acrylamide gel were in-gel
trypsinized, and the molecular weight of resulting peptides was
analyzed by MALDI-TOF. We got nine possible peptide signals
with masses (m/z) of 1251.7701, 1267.7807, 1274.8443,
1572.8253, 1612.8443, 1759.9830, 1831.9727, 1947.9883, and
1990.0351 (Fig. 2). A search of MS-Fit (algorithm by Peter
Baker and Karl Clauser) with resulting peptide masses, offered
four protein candidates originating from rat, human, and bo-
vine. Profilin II, from the human obtained the highest MOWSE
(molecular weight search) score (27.1) among four candidates.
However because of the smaller size of profilin II (15 kDa)
compared with the tentative Prx VI-binding protein (20 kDa)
and the acidic pI of human profilin II (pI, 5.78), which renders
this protein able to bind on an anion-exchange column, we
could easily rule out human profilin II from the candidates.
Other candidates, rat neuronal protein NP25 and bovine -S2
casein precursor were disregarded because of the discrepancy
in source, molecular size (24712.3 and 26018.9, respectively),
and/or pI (6.53 and 8.54, respectively). Considering the source,
molecular weight (17874.4), and the pI (8.34), rat cyclophilin A
(CyP-A) was a possible candidate for the 20-kDa Prx VI-bind-
ing protein. Four of nine peptide masses were matched with the
rat cyclophilin sequence; aa 134–144 and the same sequence
with Met-ox, aa 77–91, and aa 1–19 with a modified N-acetyl
group.
Confirmation of the 20-kDa Prx VI-binding Protein as a
CyP-A—To verify the 20-kDa tentative Prx VI-binding protein
as a CyP-A, electroblotted nitrocellulose membrane containing
proteins from High-Q fraction number 4 was probed with Prx
VI-specific antibody after overlay with Prx VI protein (Fig. 3A,
lane 4). A band of about 20 kDa was stained with the Prx
VI-specific antibody (lane 4, marked as an arrow). The 20-kDa
Prx VI overlay signal was closely matched with the hCyP-A-
specific antibody immunoblot signal of a purified recombinant
hCyP-A (Fig. 3A, lane 1) and of a High-Q column fraction 4 (Fig.
3, lane 2). In addition, the 20-kDa Prx VI overlay signals (Fig.
1B) paralleled the hCyP-A immunoblot signals of High-Q frac-
tions (Fig. 1D). To reaffirm the binding of hCyP-A to Prx VI, a
hCyP-A overlay was employed instead of the Prx VI overlay.
Prx VI was successfully recognized by the hCyP-A antiserum
after overlay with hCyP-A (Fig. 3B, lane 4) whereas the non-
overlaid control did not (Fig. 4, lane 2).
Enhancement of Prx VI Antioxidant Activity by hCyP-A—GS
protection activity of Prx VI in the presence of hCyP-A was
measured. GS protection activity of Prx VI (10 g/ml) propor-
tionally increased with the addition of hCyP-A to the assay
mixture, up to 60 g/ml. An addition of 100 g/ml or higher
concentrations of hCyP-A to the assay mixture did not further
increase the antioxidant activity of Prx VI. The activation of
Prx VI (10 g/ml) by hCyP-A reached 40% of complete protec-
tion, which corresponded to the GS activity of 40 g/ml of Prx
VI alone. hCyP-A by itself did not show considerable GS pro-
tection activity, up to 400 g/ml.
Activation of Other Prx Family Members by hCyP-A—hCyP-
A-dependent activation of other human Prx isotypes was de-
termined (Fig. 5). Basal GS protection activities were normal-
ized by the Prx protein concentration (40 g/ml for Prx I-IV and
VI, 200 g/ml for Prx V), which offered 20–40% of complete
protection. GS protection activity of Prx isotypes increased
from 1.8 to 3.4-fold by supplementing 200 g/ml of hCyP-A to
the assay mixture. The activity of Prx II and IV increased about
3.5-fold and that of Prx I, III, and VI increased by 2.2, 2.8, and
2.4-fold, respectively. The activation of Prx V was much lower
(1.8-fold) than other isotypes, however increments of activity
were consistent. Activation of Prx by CyP-A was species-spe-
cific. Neither 2-Cys Prx from budding and fission yeast, nor
from E. coli, was activated by hCyP-A (data not shown).
Reduction of Prx by hCyP-A—GS protection activity of Prx II
and VI against the thiol- and ascorbate-containing MCO sys-
tems was measured in the presence of hCyP-A (Fig. 6A).
hCyP-A supports GS protection activity of Prx II and VI in the
absence of a disulfide-reducing reagent such as DTT or 2-mer-
captoethanol, suggesting the presence of an intrinsic Prx re-
ducing activity of hCyP-A. To confirm whether the hCyP-A
itself has the capacity to reduce Prx, we investigated the hCyP-
A-dependent reduction of an intermolecular disulfide bond of
Prx II by using non-reducing SDS-PAGE analysis. Because of
the intermolecular disulfide bond, oxidized 2-Cys Prx (Prx I-IV)
containing disulfide bond(s) banded at the dimeric range
(around 45 kDa), whereas the fully reduced form banded at the
monomeric range on non-reducing SDS-PAGE gel (22). Consid-
erable reduction of Prx II was observed in the presence of 5 g
of hCyP-A (Fig. 6B, lane 2), whereas the addition of 100 M
DTT or 0.48 g of Trx (not reduced) did not reduce Prx II
FIG. 2. Peptide mass map of the
prominent 20-kDa Prx VI-binding
protein. The mass map was produced
with the eluted peptides after in-gel di-
gestion of the 20-kDa protein band with
trypsin. The mass of the peaks marked
with triangles (either filled or blank) was
submitted for data base search. The peaks
labeled with the filled triangle match cal-
culated tryptic peptide masses from rat
cyclophilin A within 50 ppm.
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considerably (Fig. 6B, lanes 3, 4). Trx (with DTT) reduced Prx
II very efficiently (Fig. 6B, lane 6); however, a supplement of
DTT (100 M) to the hCyP-A did not allow for an observable
change in the reduction of Prx II (Fig. 6B, lane 5). The thiol
group-modified hCyP-A using N-ethylmaleimide (NEM), com-
pletely lost its Prx II reducing activity (Fig. 7B, lanes 4–5). The
fact that NEM modification and the resulting inhibition of Prx
II reduction were successful without prereduction (Fig. 7B,
lane 4) suggests thiol groups, which involve the reduction of
Prx, mostly exist in reduced states during purification and
storage. To investigate the potential role of cysteine residues of
hCyP-A in Prx activation or reduction, we measured the stim-
ulation of the GS protection activity of Prx II and the Prx II
reduction activity of recombinant WT, C52S, C62S, C115S, and
C161S hCyP-A. Cys115 and Cys161 were responsible for both
stimulation of the GS protection activity and the reduction of
Prx (Fig. 8, A and B). The addition of cyclosphorin A (CsA) to an
assay mixture did not cause any detectable differences, either
in GS protection activity (data not shown) or hCyP-A-depend-
ent Prx II reduction (Fig. 7A).
DISCUSSION
Using the Prx VI (1-Cys Prx) overlay assay, we have identi-
fied CyP-A as a Prx VI-binding protein and its activation of Prx
VI antioxidant activity. We also have shown CyP-A-dependent
enhancement of GS protection activity, using all the known
human Prx isotypes. hCyP-A supported GS protection activity
of Prx II and VI even against the ascorbate-containing MCO
FIG. 3. Confirmation of CyP-A as a Prx VI-binding protein. A, 500 ng of purified recombinant hCyP-A (lane 1) and 40 l of fraction number
4 from High-Q column chromatography (lanes 2–4) were separated on a 13.5% SDS-PAGE gel and electroblotted to a nitrocellulose membrane.
Lanes 3 and 4 were incubated in the presence (lane 4) or absence (lane 3) of Prx VI and subjected to immunostaining with Prx VI antiserum. Lanes
1–2 were probed with hCyP-A specific antiserum. B, 100 ng of purified recombinant hCyP-A (lanes 1 and 3) and Prx VI (lanes 2 and 4) were
separated with 13.5% SDS-PAGE and transferred to a nitrocellulose membrane. Lanes 3 and 4 of the nitrocellulose membrane was overlaid with
5 g/ml of purified hCyP-A, and the resulting hCyP-A complexes were visualized with hCyP-A-specific antiserum. Lanes 1 and 2 of the membrane
were subjected to hCyP-A immunostaining without overlay.
FIG. 4. The concentration-depend-
ent stimulation effects of hCyP-A on
glutamine synthetase protection act-
ivity of Prx VI. Assays were performed
in a 25 l of reaction mixture containing 5
g of glutamine synthetase, 10 mM DTT,
3 M of FeCl3, 0.4 M (10 g/ml) of Prx VI
and 50 mM Hepes-NaOH buffer (pH 7.0).
hCyP-A was added to the reaction mix-
ture as indicated. The reaction was init-
iated by adding a freshly prepared DTT
and iron mixture. After 10 min of inact-
ivation at 30 °C, the remaining glutamine
synthetase activity was measured at
30 °C for 5 min by adding 1 ml of -glu-
tamyltransferase assay mixture as de-
scribed (2).
FIG. 5. Activation of various human Prx isotypes by hCyP-A.
Glutamine synthetase inactivation and measurement of residual en-
zyme activity were performed as described in the Fig. 4 legend, with Prx
proteins (Prx I-IV and Prx VI, 40 g/ml; Prx V, 200 g/ml) in the
presence (solid bar) or absence (hatched bar) of 200 g/ml of hCyP-A.
Glutamine synthetase protection activity of 200 g/ml of hCyP-A with-
out the Prx protein was shown with the blank bar.
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system, and hCyP-A-dependent reduction of Prx II was also
revealed. Considering the GS protection activity of Prx, which
comes from the intrinsic peroxidase activity of Prx (9) and the
Prx reducing activity of CyP-A (Figs. 6–7), it is reasonable to
speculate CyP-A as an immediate and a general electron donor
for the peroxidase catalysis of Prx. Ja¨schke et al. (23) reported
the binding of hCyP-A to Aop 1 (Prx III) and hCyP-A-dependent
stimulation of Aop 1 antioxidant activity (23). However the
physiological meaning of that interaction is not certain, be-
cause the cellular location of Prx III is in the mitochondrial
matrix and that of hCyP-A is cytosolic. Even though all known
human Prx isotypes were activated with hCyP-A regardless of
intracellular compartments, only the cytosolic Prx isotypes
(Prx I, II, and IV) that show the potential for physical interac-
tion with hCyP-A might have physiological relevance.
CyP was originally isolated as a CsA-binding protein, and
later calcineurin inhibiting capability when complexed with
CsA was revealed. CyPs also catalyze cis/trans interconversion
of X-Pro epitopes in proteins (24). CsA blocks the peptidyl
cis-trans-isomerase activity (PPIase activity) of CyPs by bind-
ing to the active site Trp122 residue of hCyP-A (25), whereas
each of the four Cys residues was dispensable for the binding of
CsA to hCyP-A and the PPIase activity of hCyP-A (26). Our
results and a previous report (23), which investigated the GS
FIG. 6. Identification of Prx reducing activity of hCyP-A. A, glutamine synthetase was inactivated in 25 l of a reaction mixture containing
5 g of glutamine synthetase, 10 mM ascorbate, 12.5 M FeCl3, 50 mM Hepes-NaOH (pH 7.0), and 1 g (40 g/ml) of each Prx protein with (solid
bar) or without (hatched bar) 5 g (200 g/ml) of hCyP-A. The reactions were started by adding freshly prepared iron and an ascorbate mixture.
Glutamine synthetase inactivation and a residual activity assay were done as in Fig. 4. Glutamine synthetase protection activity of hCyP-A (200
g/ml) against ascorbate system was assayed as a control (blank bar). B, purified Prx II (1 g) was incubated in a 100 mM sodium phosphate buffer
(pH 7.0) with 5 g of hCyP-A (lanes 2 and 5) or with 0.48 g of Trx in the absence (lanes 1–3) or presence (lanes 4–6) of 100 M DTT. The volume
of the reaction mixtures was 25 l. Samples containing 200 ng of Prx II were analyzed on a 12% SDS-PAGE gel without 2-mercaptoethanol, and
the separated Prx II protein bands were visualized by Western immunostaining with Prx II-specific antiserum.
FIG. 7. Effects of cyclosporin A and thiol group modification of hCyP-A on the hCyP-A-dependent reduction of Prx II. A, Prx II (100
ng) was incubated for 10 min at room temperature in the presence 3.4 g of cyclosporin A (lane 1) or in the presence of 400 ng of hCyP-A (lane 2)
or in the presence of 3.4 g of cyclosporin A and 400 ng of hCyP-A (lane 3). Protein samples were separated on a 12% SDS-PAGE gel without
2-mercaptoethanol and the Prx II protein bands were visualized by Western immunostaining with Prx II-specific antiserum. B, Prx II (100 ng) was
incubated at room temperature for 10 min with 500 ng of hCyP-A in the absence (lane 2) or presence of 100 M DTT (lane 3), with 500 ng of
N-ethylmaleimide (NEM)-modified hCyP-A, which was previously reduced with DTT (lane 5) or without prereduction (lane 4). Resulting Prx II
reduction was analyzed with 12% SDS-PAGE under non-reducing conditions. hCyP modification was done in a TBS buffer (25 mM Tris-HCl buffer,
pH 9.5, containing 137 mM NaCl, and 2.7 mM KCl) with 25 mM NEM for 1 h at room temperature. DTT reduction prior to NEM modification of
hCyP-A was performed with 10 mM DTT for 1 h at room temperature in a TBS buffer. After the modification with NEM, samples were dialyzed
overnight with a TBS buffer.
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protection activity of Prx II or Prx III and the reduction of Prx
II (Fig. 7), clearly demonstrate the CsA independence of CyP-A
binding and activation of Prx isotypes. Numerous reports have
been published that state CsA protects cells against oxidative
injury caused by anoxia/reoxygenation (27–29), added perox-
ides (30–31), and treatment of various cytotoxic agents (28,
31–32). In experimental models that investigate the function-
ing of the mitochondrial permeability transition (MPT) pore for
the protective effects of CsA, the mitochondrial isoform, CyP-D
was the primary target for protection. CyP-D selectively tar-
geted to the voltage-dependent anion channel-adenine nucleo-
tide translocase (VDAC-ANT) complex (the core component of
the PT pore), which has been known to be involved in cell
necrosis induced by oxidative stress and impaired Ca2 home-
ostasis (reviewed in Ref. 33). CsA blocks the PT pore presum-
ably because of the simple occupation of the active site of
CyP-D (34). As a consequence, the PT pore blockage by CsA is
a calcinurin-independent process (35–36). However, consider-
ing the MPT prevention capacity of extra-mitochondrially
added Prx (37), the physiological meaning of CyP-A-dependent
activation of Prx enzymes can be considered as one of the most
important CsA-independent MPT-maintaining processes in the
cell. For investigation of the details of MPT-implicated Prx
functioning, CyP-D/Prx III (mitochondrial Prx isotype) interac-
tion will be explored, as well as CyP-A binding to cytosolic Prx
isotypes.
In the neuronal cell model, protection of CsA is consistent
with calcineurin inhibition, which prevents the dephosphoryl-
ation of nitric oxide synthetase and its subsequent activation
(38). In this case, CyP-A, which is localized to the cytosol, is
presumably the best candidate for the inhibition of calcineurin
by complexing with CsA. However, CsA-insensitive protection
of cells by CyP-A has been reported in organic peroxide-
stressed myocytes (39). Until recently, intrinsic antioxidant or
redox activity of CyP-A has not been reported. Therefore,
CyP-A protects the myocytes against peroxides through the
enhancement of the peroxidase activity of Prx by supplying the
reducing equivalents, and this could be a reasonable explana-
tion in this experimental model.
Among the four Cys residues (Cys52, Cys62, Cys115, Cys161) of
hCyP-A, Cys115 and Cys161 were responsible for the reduction
and the activation of Prx (Fig. 7). The distance between
Cys115 and Cys161 is calculated to be 20.08 Å (SYBYL, Tripos.
Inc.), and the two Cys residues are localized at opposite sides
in the globular structure of hCyP-A (1VBS.pdb). Conse-
quently, the formation of intramolecular disulfide linkage
between Cys115 and Cys161 through the reduction of Prx is not
assumed to be possible. Considering the exposed (Cys161) and
partially buried (Cys115) status in the globular structure,
intermolecular disulfide bond formation involving two Cys161
residues is feasible, but not between two Cys115 residues or
Cys115–Cys161, unless considerable conformational changes
occur. In addition, the possibility of either one of the two or
both of the Cys residues oxidizing to sulfinic acid through
sulfenic acid coupled to Prx reduction cannot be ignored.
Further study of ultimate physiological electron donor and
tentative cyclophilin reductase will be necessary for elucidat-
ing the mechanism of the electron flow of cyclophilin-coupled
Prx functioning.
Although various biological functions and activities have
been reported with respect to Prx proteins such as an inhibition
of apoptosis (40), an inhibition of c-Abl tyrosine kinase activity
(41), a regulation of NK-B and AP-1 (4, 42), and a peroxinitrite
reductase activity (43), only the peroxidase activity is com-
monly accepted as the catalytic activity of Prx. More than a
thousand times higher affinity (10 M) to H2O2 than that of
catalase (25 mM) (10, 44), inhibition of the peroxidase activity of
Prx with a relatively higher (100 M) concentration of perox-
ide,2 and an abundance of Prx proteins in various cells or
tissues (44), lead us to assume that Prx proteins might be
functioning to remove particularly low concentrations of perox-
ide that are produced as a second messenger. Recently, growing
evidence suggests a transient and modicum generation of hy-
drogen peroxide as part of membrane receptor signaling (re-
viewed in Ref. 45). A report that demonstrates the capacity of
Prx, which removes hydrogen peroxide generated in growth
signaling (46), supports this assumption. The detailed role of
isotype-specific Prx/CyP-A complex in the membrane-receptor
signaling as one of the possible signal modulators remains to be
evaluated.
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